# OnCo record nct03301168 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct03301168/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct03301168", "NCT03301168" ;
  schema:name "Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant"@en ;
  schema:description "A phase 1/2 trial of BPX-501 T cells in acute lymphoblastic leukaemia, acute myeloid leukaemia, non-Hodgkin lymphoma and myelodysplastic syndromes / neoplasms, run by Bellicum Pharmaceuticals, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct03301168/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03301168> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2014-04" ;
  onco:cancers <https://onco.cc/cancers/all-leukemia/>, <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/non-hodgkin-lymphoma/>, <https://onco.cc/cancers/mds/>, <https://onco.cc/cancers/aml-paediatric/> ;
  onco:companies <https://onco.cc/companies/bellicum/> .